Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary. Giovannoni G. Mult Scler 2023;29:1068-1069.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Giovannoni G. Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary. Mult Scler 2023;29:1068-1069.
PMID: 37489807